Provell Pharmaceuticals and Mark Cuban Cost Plus Drug Company Bring Leading Hypothyroid Drug, Euthyrox, to U.S. Patients at Low-Cost Prices Through Direct-to-Consumer Model
Provell Pharmaceuticals and Mark Cuban Cost Plus Drug Company Bring Leading Hypothyroid Drug, Euthyrox, to U.S. Patients at Low-Cost Prices Through Direct-to-Consumer Model
HONEY BROOK, Pa., March 12, 2024 /PRNewswire/ -- Provell Pharmaceuticals, a healthcare company that distributes world-class, branded drugs at generic prices by eliminating middlemen markups, today announced a partnership with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) to offer patients direct access to a leading hypothyroid drug, Euthyrox, at low-cost prices on the Cost Plus Drugs online platform. Euthyrox (levothyroxine sodium) is one of the most widely prescribed drugs worldwide1 to treat hypothyroidism, available in over 110 countries and FDA approved in 2018. It is now offered in the U.S. through Cost Plus Drugs and in retail pharmacies.
賓夕法尼亞州霍尼布魯克，2024年3月12日 /PRNewswire/ — 通過取消中間商加價以仿製藥價格分銷世界一流品牌藥物的醫療保健公司Provell Pharmicals今天宣佈與PBC（Cost Plus Drugs）的Mark Cuban Cost Plus藥品公司建立合作伙伴關係，在Cost Plus Drugs在線平台上以低成本爲患者直接提供領先的甲狀腺功能減退藥物Euthyrox。Euthyrox（左旋甲狀腺素鈉）是全球處方最廣泛的藥物之一1 用於治療甲狀腺功能減退，已在110多個國家上市，並於2018年獲得美國食品藥品管理局批准。現在，它在美國通過Cost Plus Drugs和零售藥房提供。
"Our mission is to remove the cost barrier for millions of Americans, regardless of insurance coverage, who need quality medications but who often cannot afford them due to markups imposed by a variety of players in the U.S. healthcare landscape," said Steve Hodge, CEO at Provell Pharmaceuticals. "By working directly with online platforms such as Cost Plus Drugs, which shares our vision to make drugs affordable and accessible to all, we are disrupting the traditional model and conferring significant savings to patients."
Provell Pharmicals首席執行官史蒂夫·霍奇表示：“我們的使命是消除數百萬美國人的成本壁壘，無論保險範圍如何，他們需要優質的藥物，但由於美國醫療保健領域各種參與者強加的加價，他們往往負擔不起。”“通過直接與諸如Cost Plus Drugs之類的在線平台合作，我們正在顛覆傳統模式，爲患者節省大量資金，這與我們有着共同的願景，即讓所有人都能負擔得起藥物。”
Currently, the U.S. healthcare system consists of complex pricing mechanisms, for both brand and generic medications, that artificially inflate prices. In an emerging new model, companies such as Provell Pharmaceuticals create partnerships with manufacturers to bring well established, globally recognized drugs through the FDA approval process and introduce them to the U.S. market. Bypassing the intermediaries that impose these often-convoluted pricing structures on the U.S. healthcare system enables Provell to offer name brand products at low prices to consumers and physicians.
目前，美國醫療體系由複雜的品牌和仿製藥定價機制組成，這些機制人爲地抬高了價格。在一種新興的新模式中，Provell Pharmaceuticals等公司與製造商建立合作伙伴關係，通過美國食品藥品管理局的批准程序提供成熟的、全球認可的藥物，並將其引入美國市場。繞過將這些經常錯綜複雜的定價結構強加給美國醫療體系的中介機構，使Provell能夠以低廉的價格向消費者和醫生提供名牌產品。
"Drug prices continue to rise exponentially, and it's an unsustainable trend that is extracting a huge toll on the health and well-being of many Americans," said Alex Oshmyansky, MD, PhD, CEO and Co-Founder of Cost Plus Drugs.
Cost Plus Drugs首席執行官兼聯合創始人亞歷克斯·奧什米揚斯基醫學博士、博士、首席執行官兼聯合創始人亞歷克斯·奧什米揚斯基說：“藥品價格繼續呈指數級上漲，這是一種不可持續的趨勢，給許多美國人的健康和福祉造成了巨大損失。”
"We've developed an alternative model -- and are partnering with like-minded companies such as Provell Pharmaceuticals—to offer prescription drugs directly to consumers at a fraction of the cost by showing consumers exactly what the drugs cost, exactly what our margin is, and exactly what consumers will pay. It's fair, transparent, and is dramatically less expensive for patients."
“我們已經開發了一種替代模式，並正在與Provell Pharmaceuticals等志同道合的公司合作，通過向消費者展示藥品的確切成本、確切的利潤率以及消費者將要支付的確切費用，直接向消費者提供處方藥，而成本只是其中的一小部分。它公平、透明，而且對患者來說要便宜得多。”
Low-Cost Model is Gaining Traction
低成本模式越來越受歡迎
Euthyrox is the latest example of a branded drug that would be prohibitively expensive if sold through traditional U.S. pricing models. But, under Provell Pharmaceuticals' unique business model—a lean structure with less than 10 employees, no sales force, and direct licensure of Euthyrox from Merck KGaA, Darmstadt, Germany—overhead is exponentially lower compared to a traditional pharmaceutical company.
Euthyrox是品牌藥物的最新例子，如果通過傳統的美國定價模式出售，其價格將高得令人望而卻步。但是，在Provell Pharmaceuticals獨特的商業模式下，即員工少於10人的精益結構，沒有銷售隊伍，直接獲得德國達姆施塔特默沙東KGaA的Euthyrox許可，與傳統制藥公司相比，管理費用要低得多。
"Not only is the size and scope of Provell lean and nimble, but the massive scale and power of Merck KGaA, Darmstadt, Germany as one of the world's largest pharmaceutical manufacturers provides economies of scale that are difficult to match," said Hodge. "We want to give autonomy back to the provider and the patient to not only know where their medicine comes from but also treat their disease with low-cost branded drugs that are effective and affordable for all."
霍奇說：“Provell不僅規模和範圍精益靈活，而且德國達姆施塔特的默沙東KGaA作爲全球最大的製藥製造商之一，其龐大的規模和實力提供了難以匹敵的規模經濟。”“我們希望將自主權交還給提供者和患者，不僅要知道他們的藥物來自哪裏，而且要使用所有人都能負擔得起的低成本品牌藥物來治療他們的疾病。”
Euthyrox is Provell's first licensed drug for marketing and distribution in the U.S., but future plans include additional legacy brands and specialty pharmaceutical products. As with Euthyrox, each newly licensed drug will undergo rigorous testing required by the FDA to ensure bioequivalence with competitor drugs on the market. Provell Pharmaceuticals has also invested in the higher cost of blister packaging to preserve the potency of Euthyrox and ensure a consistent therapeutic dosage is delivered in every pill. This attention to preserving potency is especially important in this class of drug which is deemed a narrow therapeutic index (NTI) category by the FDA. Recent studies have shown the benefits of blister packaging preserving tablet potency better than traditional pharmacy bottles used in the US.2
Euthyrox是Provell在美國上市和分銷的第一種獲得許可的藥物，但未來的計劃包括其他傳統品牌和特種藥品。就像 Euthyrox 一樣，每種新獲得許可的藥物都將經過美國食品藥品管理局要求的嚴格測試，以確保與市場上競爭對手藥物具有生物等效性。Provell Pharmaceuticals還投資了更高的吸塑包裝成本，以保持Euthyrox的效力，並確保每粒藥丸的治療劑量一致。這種對保持效力的關注在這類被美國食品藥品管理局視爲狹義治療指數（NTI）類別的藥物中尤爲重要。最近的研究表明，吸塑包裝比美國使用的傳統藥瓶更能保持藥片效力。2
About Provell Pharmaceuticals
關於 Provell 製藥公司
Provell Pharmaceuticals is a U.S. healthcare company that markets and distributes world-class, branded pharmaceutical products at low-cost, generic prices through a disruptive business model that eliminates costly markups from pharmacy benefit management (PBMs) and insurers in order to save patients money on their medications. By partnering with European drug manufacturers to distribute their drugs directly to U.S. consumers, Provell Pharmaceuticals is able to remove costs barriers that prevent patients from accessing the prescription drugs they need. Direct sourcing from Europe allows for Trade Agreement Act (TAA) compliance and mitigates supply chain risks posed by unforeseen global events. Provell Pharmaceuticals is currently licensed to market and distribute Euthyrox, a branded drug to treat hypothyroidism, throughout the U.S.
Provell Pharmaceuticals是一家美國醫療保健公司，通過顛覆性的商業模式以低成本的仿製藥價格銷售和分銷世界一流的品牌藥品，該模式取消了藥房福利管理（PBM）和保險公司的昂貴加價，從而爲患者節省藥費。通過與歐洲藥品製造商合作，將藥物直接分銷給美國消費者，Provell Pharmicals能夠消除阻礙患者獲得所需處方藥的成本壁壘。直接從歐洲採購可以遵守《貿易協定法》（TAA），並減輕不可預見的全球事件帶來的供應鏈風險。Provell Pharmicals目前已獲准在美國各地銷售和分銷治療甲狀腺功能減退的品牌藥物Euthyrox。
About Euthyrox
關於 Euthyrox
Please refer to the full prescribing label and important safety information:
請參閱完整的處方標籤和重要的安全信息：
References: 1. Data on file. Merck KGaA, Darmstadt, Germany. 2. Chun J. Stability of levothyroxine tablets in blister packaging versus bottles and vials under simulated in-use conditions. AAPS Open. 2022;8:15. Accessed January 14, 2023.
參考文獻： 1。 存檔的數據。默沙東 KGaA，德國達姆施塔特。 2。 Chun J. 泡罩包裝中左旋甲狀腺素片劑在模擬使用條件下與瓶子和小瓶的穩定性對比。AAPS 公開賽。2022；8:15。已於 2023 年 1 月 14 日訪問。
PP-RG-00241
PP-RG-00241
Related Links:
相關鏈接：
SOURCE Provell Pharmaceuticals LLC
來源 Provell 製藥有限責任公司
譯文內容由第三人軟體翻譯。